Advances and challenges in precision medicine in salivary gland cancer

Salivary gland cancer (SGC) is a distinct but heterogeneous group of malignancies comprising approximately 6.5% of cases within head and neck cancer [1]. This makes it a rare cancer, with an estimated age-standardized annual incidence of less than 2/100.000 in most countries [2]. The most recent World Health Organization classification of Head and Neck Tumours distinguishes 22 histopathological subtypes of SGC, which makes each subtype even rarer [3]. Recognition of, and differentiation between these different subtypes is notoriously difficult and different subtypes exhibit different clinical features adding up to the complexity of the disease [4].

Source: Cancer Treatment Reviews - October 13, 2019 Category: Cancer & Oncology Authors: Gerben Lassche, Wim van Boxtel, Marjolijn J.L. Ligtenberg, Adriana C.H. van Engen-van Grunsven, Carla M.L. van Herpen Tags: Tumour Review Source Type: research